Evaluating a new biomarker for early kidney injury detection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on critically ill patients at high risk of acute kidney injury (AKI) to assess the clinical utility of urinary dickkopf-3 (uDKK3) as an early predictor of kidney dysfunction. By monitoring patients in the intensive care unit at Saarland University Hospital, the study aims to determine if uDKK3 can provide earlier indications of AKI compared to traditional markers like creatinine. The progression of kidney function will be tracked over a period of up to two years, allowing for a comprehensive evaluation of this biomarker's effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients treated on the intensive care units of Saarland University Hospital.

Exclusion Criteria:

* Patients on renal replacement treatment before admission to the intensive care unit.
* Patients with chronic kidney disease stage CKD G3b or below.
* Known kidney disease.
* Kidney transplantation.
* Intoxications leading to dialysis treatment.
* Participation in other clinical trials.

Where it's running

• Universitätsklinikum des Saarlandes
  Homburg, Saarland, Germany Recruiting

Study contacts

• Principal investigator: Stefan Neuhaus, MD — Universität des Saarlandes
• Study coordinator: Stefan Neuhaus, MD
• Email: stefan.neuhaus@uks.eu
• Phone: +4968411615041

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI

  This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07749417

• Restarting RAS inhibitors after AKI: a quick test in hospitalized adults

  This pilot study tests whether restarting renin-angiotensin system inhibitors early after acute kidney injury is feasible and safe in hospitalized adults already using these medicines.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT07734636

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.